生脉注射液对乳腺癌表柔比星多程化疗心脏毒性的作用

目的探析生脉注射液对乳腺癌表柔比星多程化疗心脏毒性的作用。方法选取2015年1月至2019年8月在我院接受化疗的60例乳腺癌患者,将其随机分为对照组(n=30)与观察组(n=30)。对照组患者给予AC方案(表柔比星+多西他赛)化疗,观察组患者在对照组基础上给予生脉注射液。比较两组患者临床疗效、心电图异常率、心肌酶谱指标及不良反应发生情况。结果对照组临床总缓解率为33.33%,观察组为53.33%,两组临床总缓解率比较,差异无统计学意义(P>0.05)。对照组心电图异常率为30.00%,观察组为16.67%,两组心电图异常率比较,差异无统计学意义(P>0.05)。治疗后,对照组CK、CKMB、cTnT水平显著升高,观察组cTnT水平显著升高,且观察组CK、CKMB、cTnT水平显著低于对照组(P<0.05)。观察组不良反应总发生率为16.67%,显著低于对照组的46.67%(P<0.05)。结论在乳腺癌表柔比星多程化疗中应用生脉注射液,能够显著减轻心脏毒性,且不良反应发生率较低,值得临床进一步应用与借鉴。

Effect of Shengmai injection on cardiac toxicity of multistage chemotherapy with epirubicin in breast cancer

Objective To explore the effect of Shengmai injection on cardiac toxicity of multistage chemotherapy with epirubicin breast cancer patients.Methods A total of 60 breast cancer patients who received chemotherapy in our hospital from January 2015 to August 2019 were selected and randomly divided into control group(n=30)and observation group(n=30).Patients in the control group were given AC regimen chemotherapy(epirubicin+docetaxel),and patients in the observation group were given Shengmai injection on the basis of the control group.The clinical efficacy,abnormal rate of electrocardiogram,myocardial enzyme indexes and adverse reactions in the two groups were compared.Results The total clinical remission rate was 33.33%in the control group and 53.33%in the observation group.There was no significant difference in the total clinical remission rate between the two groups(P>0.05).The abnormal rate of electrocardiogram was30.00%in the control group and 16.67%in the observation group.There was no significant difference in the abnormal rate of electrocardiogram between the two groups(P>0.05).After treatment,the levels of CK,CKMB and cTnT in the control group increased significantly,the level of cTnT in the observation group increased significantly,and the levels of CK,CKMB and cTnT in the observation group were significantly lower than those in the control group(P<0.05).The total incidence of adverse reactions in the observation group was 16.67%,which was significantly lower than that 46.67%in the control group(P<0.05).Conclusion Application of Shengmai injection in multistage chemotherapy with epirubicin in breast cancer can significantly reduce cardiac toxicity,and has lower incidence of adverse reactions,which is worthy of further clinical application and reference.